Onesource Specialty Pharma · NSE: ONESOURCE · BSE: 544292
Q4 FY26 results · Jan–Mar 2026
Onesource Specialty Pharma reported revenue from operations of ₹428.22 crore (up 0.5% from Q4 FY25) and net profit of ₹4.60 crore (down 95.3% from Q4 FY25) for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 428.22 | 425.95 | +0.5% | 290.34 | +47.5% |
| Other income | 2.09 | 2.89 | −27.6% | 4.62 | −54.7% |
| Total income | 430.31 | 428.84 | +0.3% | 294.96 | +45.9% |
| Profit before tax | (0.29) | 83.50 | Turned loss | (93.01) | Loss narrowed |
| Net profit for the period | 4.60 | 98.20 | −95.3% | (88.70) | Turned profit |
| EPS, basic (₹) | 0.40 | 8.61 | −95.4% | (7.74) | Turned profit |
| Net margin (%) | 1.1 | 23.1 | -30.6 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 418.96 | 477.41 | −12.2% | 290.22 | +44.4% |
| Other income | 2.09 | 3.91 | −46.5% | 4.62 | −54.7% |
| Total income | 421.06 | 481.32 | −12.5% | 294.84 | +42.8% |
| Profit before tax | 21.48 | 174.88 | −87.7% | (62.19) | Turned profit |
| Net profit for the period | 21.48 | 174.19 | −87.7% | (62.19) | Turned profit |
| EPS, basic (₹) | 1.87 | 15.28 | −87.8% | (5.43) | Turned profit |
| Net margin (%) | 5.1 | 36.5 | -21.4 |
Consolidated
- Filed with BSE
- 13 May 2026, 18:52 IST
- Board meeting
- 13 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 May 2026, 18:52 IST
- Board meeting
- 13 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE